In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sygnis AG

www.sygnis.com

Latest From Sygnis AG

DEALS ROUND-UP: M&A and partnering 1-28 December

As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.

Metabolic Disorders Infectious Diseases

Hopp’s bitter harvest as Wilex wanes and Sygnis sings swansong

While Dietmar Hopp clearly had a Midas touch when it came to investing in technology, the billionaire SAP founder has not had the same luck in the life sciences. Strategic changes will have to be on the cards at Wilex and Sygnis Pharma, two of dievini Hopp BioTech's leading portfolio companies.

Cancer Spain

Hopp not wavering but sinking €80m into CureVac

It's not easy to raise large sums of cash for biotech drug development these days, so having software billionaire Dietmar Hopp on side is an enviable position to be in. And despite the recent blow to his portfolio dealt by the late-stage failure of Agennix's talactoferrin (scripintelligence.com, 7 August 2012), his commitment to biotech is "unwavering", according to one of the key curators of his biotech portfolio, Dr Friedrich von Bohlen. Today's announcement by CureVac would appear to demonstrate this.

Cardiovascular Cancer

Efficacy study of Sygnis's G-CSF in stroke under way

The German company Sygnis Pharma expects clinical data from its Phase II study of its G-CSF product, AX200, in acute ischaemic stroke, to be available in the middle of 2011.

Cardiovascular Orthopedics
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
    • Synthesis Technologies, Production Processes
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Sygnis Pharma AG
  • Lion bioscience AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Sygnis AG
  • Senior Management
  • Heikki Lanckriet, PhD, CEO, CSO
    David Roth, PhD, CFO
  • Contact Info
  • Sygnis AG
    Phone: (49) 6221 3540 120
    Waldhofer Str. 102
    Heidelberg, 69123
    Germany
UsernamePublicRestriction

Register